Literature DB >> 20170870

In-hospital outcomes of contemporary percutaneous coronary intervention in patients with chronic total occlusion insights from the J-CTO Registry (Multicenter CTO Registry in Japan).

Yoshihiro Morino1, Takeshi Kimura, Yasuhiko Hayashi, Toshiya Muramatsu, Masahiko Ochiai, Yuichi Noguchi, Kenichi Kato, Yoshisato Shibata, Yoshikazu Hiasa, Osamu Doi, Takehiro Yamashita, Takeshi Morimoto, Mitsuru Abe, Tomoaki Hinohara, Kazuaki Mitsudo.   

Abstract

OBJECTIVES: Our aim was to investigate in-hospital outcomes of percutaneous coronary intervention (PCI) of chronic total occlusion (CTO) using contemporary techniques.
BACKGROUND: Despite its increasing popularity and technical complexity, clinical outcomes of PCI for CTO using contemporary techniques have not been adequately evaluated.
METHODS: The J-CTO registry (multicenter CTO registry in Japan) is a large scale, multicenter registry enrolling consecutive patients undergoing PCI for CTO from 12 Japanese centers. In-hospital clinical outcomes were evaluated in 498 patients with 528 CTO lesions.
RESULTS: Multiple wiring strategies were frequently attempted (parallel wiring 31% and retrograde approach 25%) with relatively long guidewire manipulation time (median 30 min). Utilizing these complex strategies, high procedural success rates (88.6% in the first attempt cases and 68.5% in the retry cases) were accomplished. In-hospital adverse event rates were strikingly low (cardiac death 0.2%, Q-wave myocardial infarction 0.2%, and stroke 0%). Potential disadvantages of these procedures, including a large amount of contrast volume (median 293 ml) and long fluoroscopic time (median 45 min), were not associated with serious clinical sequelae (contrast induced nephropathy 1.2% and radiation dermatitis 0%). Although coronary perforations were documented frequently by angiography (antegrade 7.2% and retrograde 13.6%), clinically significant perforation resulting in cardiac tamponade was rare (0.4%).
CONCLUSIONS: Most CTO lesions can be safely and successfully treated with PCI utilizing contemporary advanced techniques. Invasiveness and potential risks of these strategies, which have been the greatest concerns of CTO treatment, may be acceptable in the majority of cases considering the actual incidences of related adverse events and the procedural success rates. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20170870     DOI: 10.1016/j.jcin.2009.10.029

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  56 in total

1.  Collagenase Total Occlusion-1 (CTO-1) trial: a phase I, dose-escalation, safety study.

Authors:  Bradley H Strauss; Azriel B Osherov; Sam Radhakrishnan; G B John Mancini; Allison Manners; John D Sparkes; Robert J Chisholm
Journal:  Circulation       Date:  2011-12-16       Impact factor: 29.690

2.  Comparison of magnetic wire navigation with the conventional wire technique for percutaneous coronary intervention of chronic total occlusions: a randomised, controlled study.

Authors:  Christian Roth; Rudolf Berger; Sabine Scherzer; Lisa Krenn; Clemens Gangl; Daniel Dalos; Georg Delle-Karth; Thomas Neunteufl
Journal:  Heart Vessels       Date:  2015-09-14       Impact factor: 2.037

3.  Intravascular ultrasound-guided bail-out therapy in a case of acute myocardial infarction with iatrogenic coronary artery spiral dissection.

Authors:  Teruo Okabe; Hiroki Kitakata; Yasuo Kurita; Narutaka Ohashi; Yukiko Karube; Satoshi Ogawa
Journal:  J Cardiol Cases       Date:  2014-08-05

4.  Radial approach and single wiring as first intentional strategies in chronic total occlusions of the left anterior descending coronary artery.

Authors:  Yasser Nassar; Nicolas Boudou; Didier Carrie
Journal:  J Saudi Heart Assoc       Date:  2013-03-16

5.  Temporal trends of fluoroscopy time and contrast utilization in coronary chronic total occlusion revascularization: insights from a multicenter United States registry.

Authors:  Tesfaldet T Michael; Dimitri Karmpaliotis; Emmanouil S Brilakis; Mohammed Alomar; Shuaib M Abdullah; Ben L Kirkland; Katrina L Mishoe; Nicholas Lembo; Anna Kalynych; Harold Carlson; Subhash Banerjee; Michael Luna; William Lombardi; David E Kandzari
Journal:  Catheter Cardiovasc Interv       Date:  2014-01-31       Impact factor: 2.692

Review 6.  A contemporary review of clinical significances of percutaneous coronary intervention for chronic total occlusions, with some Japanese insights.

Authors:  Yoshihiro Morino
Journal:  Cardiovasc Interv Ther       Date:  2021-03-03

Review 7.  Approach to CTO Intervention: Overview of Techniques.

Authors:  Aris Karatasakis; Barbara Anna Danek; Dimitri Karmpaliotis; Khaldoon Alaswad; Minh Vo; Mauro Carlino; Mitul P Patel; Stéphane Rinfret; Emmanouil S Brilakis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-01

8.  Impact of multi-vessel versus single-vessel disease on outcomes after percutaneous coronary interventions for chronic total occlusions.

Authors:  Aurel Toma; Barbara E Stähli; Michael Gick; Cathérine Gebhard; Thomas Nührenberg; Kambis Mashayekhi; Miroslaw Ferenc; Franz-Josef Neumann; Heinz Joachim Buettner
Journal:  Clin Res Cardiol       Date:  2017-02-24       Impact factor: 5.460

9.  What the surgeon needs to know about percutaneous coronary intervention treatment of chronic total occlusions.

Authors:  Satoru Mitomo; Ozan M Demir; Antonio Colombo; Sunao Nakamura; Alaide Chieffo
Journal:  Ann Cardiothorac Surg       Date:  2018-07

10.  The efficacy of "hybrid" percutaneous coronary intervention in chronic total occlusions caused by in-stent restenosis: insights from a US multicenter registry.

Authors:  Georgios Christopoulos; Dimitri Karmpaliotis; Khaldoon Alaswad; William L Lombardi; J Aaron Grantham; Bavana V Rangan; Anna P Kotsia; Nicholas Lembo; David E Kandzari; James Lee; Anna Kalynych; Harold Carlson; Santiago Garcia; Subhash Banerjee; Craig A Thompson; Emmanouil S Brilakis
Journal:  Catheter Cardiovasc Interv       Date:  2014-07-04       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.